Westmount Partners LLC Raises Holdings in Neonc Technologies Holdings, Inc. $NTHI

Westmount Partners LLC raised its holdings in Neonc Technologies Holdings, Inc. (NASDAQ:NTHI) by 355.2% during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 197,178 shares of the company’s stock after purchasing an additional 153,858 shares during the quarter. Westmount Partners LLC’s holdings in Neonc Technologies were worth $893,000 as of its most recent SEC filing.

Other hedge funds have also modified their holdings of the company. Royal Bank of Canada acquired a new stake in shares of Neonc Technologies during the 1st quarter worth about $247,000. Bank of America Corp DE acquired a new position in Neonc Technologies in the second quarter valued at about $801,000. Vanguard Group Inc. purchased a new position in Neonc Technologies during the third quarter worth about $1,279,000. HighPoint Advisor Group LLC increased its position in shares of Neonc Technologies by 20.5% during the fourth quarter. HighPoint Advisor Group LLC now owns 1,144,640 shares of the company’s stock valued at $9,466,000 after acquiring an additional 194,408 shares during the last quarter. Finally, Goldman Sachs Group Inc. purchased a new stake in shares of Neonc Technologies in the 4th quarter valued at approximately $124,000.

Neonc Technologies Price Performance

Shares of NTHI opened at $3.50 on Friday. Neonc Technologies Holdings, Inc. has a 1 year low of $3.01 and a 1 year high of $12.99. The company’s 50-day simple moving average is $4.20 and its 200-day simple moving average is $6.28.

Neonc Technologies (NASDAQ:NTHI) last announced its quarterly earnings data on Friday, May 15th. The company reported ($0.38) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.22) by ($0.16).

Wall Street Analyst Weigh In

A number of equities analysts recently weighed in on NTHI shares. Maxim Group started coverage on shares of Neonc Technologies in a research report on Monday, May 18th. They set a “buy” rating and a $20.00 price objective for the company. BTIG Research reissued a “buy” rating and issued a $15.00 target price on shares of Neonc Technologies in a research report on Tuesday, May 26th. Weiss Ratings cut Neonc Technologies from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Wednesday, June 24th. Finally, Alliance Global Partners assumed coverage on Neonc Technologies in a research report on Tuesday, May 19th. They set a “buy” rating and a $13.00 price target for the company. Three equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $16.00.

Neonc Technologies Profile

Neonc Technologies Holdings, Inc develops novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. Its lead products in development include NEO100, which is in Phase 2a clinical trials for treating glioblastoma; and NEO212, a covalently conjugated molecule combining the chemotherapeutic drug temozolomide with perillyl alcohol that is completed preclinical testing. The company was incorporated in 2023 and is based in Los Angeles, California.